

Supplementary Information for

**Investigation of the Superoxide Anion-Triggered
Chemiluminescence of Coelenterazine Analogs**

Table of Contents

1. General Synthetic Procedures	3
1.1. 6-(4-Fluorophenyl)-2-methylimidazo[1,2-a]pyrazin-3(7H)-one (CLA-2)	4

1. General Synthetic Procedure

Reagents and solvents were purchased from Merck and used without further purification. All reactions involving oxygen or moisture-sensitive compounds were carried out under dry nitrogen atmosphere. Ice-water and silicon baths were used for reactions at low and high temperatures, respectively, with all reaction temperatures referring to the external bath. Organic extracts were dried over anhydrous Na₂SO₄, filtered and concentrated using a rotary evaporator (Büchi® Rotavapor® R-210, Büchi® B-491 Heating Bath 120V, KNF Neuberger D-79112 Vacuum Pump N 035.1.2 AN.18).

Reactions were monitored by thin-layer chromatography (TLC) using aluminum-backed Merck 60 F₂₅₄ silica gel plates and *n*-hexanes-ethyl acetate solvent systems. After visualization under ultraviolet light at 254 nm and 365 nm, the plates were developed by immersion in a solution containing a mixture of *p*-anisaldehyde (2.5%), acetic acid (1%), and sulfuric acid (3.4%) in 95% ethanol followed by heating. Compounds were systematically named following IUPAC recommendations with ChemDraw v20.0.0.41 (Perkin-Elmer, Waltham, MA, USA).

NMR spectra were recorded in Acetone-d₆ or MeOH-d₄ solutions on a Bruker NMR spectrometer (Bruker Advance III 400 MHz Ascend, 9.4 Tesla), and chemical shifts are reported on the δ scale (ppm) using the residual solvent signals [δ = 2.050 ppm (¹H, qu, Acetone-d₆), 2.840 (¹H, s, Acetone-d₆)] or [δ = 3.31 ppm (¹H, qu, MeOH-d₄), 4.78 ppm (¹H, s, MeOH-d₄)] as internal standards. Coupling constants (*J*) are reported in Hz. FT-MS analysis were done on a LTQ Orbitrap™ XL hybrid mass spectrometer (Thermo Fischer Scientific, Bremen, Germany) controlled by LTQ Tune Plus and Xcalibur 2.1.0.

ESI = Electrospray ionization; EtOAc = Ethyl acetate; EtOH = Ethanol; NMR = Nuclear magnetic resonance; FT-MS = Fourier transform mass spectrometry; qu = quintet; *r.t.* = Room temperature; s = singlet.

1.1. 6-(4-Fluorophenyl)-2-methylimidazo[1,2-*a*]pyrazin-3(7*H*)-one (CLA-2)

A solution of 3-bromo-5-(4-fluorophenyl)pyrazin-2-amine (**F-Clm**) (0.931 mmol, 1 equiv) and methylglyoxal (1.396 mmol, 1.5 equiv) in EtOH (9 mL) was deoxygenated with N₂. Then the resulting mixture was cooled to 0 °C, HCl (37%, 3.35 mmol, 3.6 equiv) was added, and the solution was stirred up to room temperature, and stirred first at 70 °C for 2.5 h and then at r.t. overnight. The resulting solution was concentrated under reduced pressure to give a brown oil, which was redissolved in the minimum amount of EtOAc, precipitated with diethyl ether, and vacuum-dried to afford 6-(4-fluorophenyl)-2-methylimidazo[1,2-*a*]pyrazin-3(7*H*)-one (**CLA-2**) as an ochre solid [0.212 g, 94 %].

¹H NMR (400 MHz, Acetone) δ = 9.31 – 9.30 (d, *J* = 1.3 Hz, 1H), 9.26 – 9.24 (d, *J* = 1.4 Hz, 1H), 8.24 – 8.19 (m, 2H), 7.33 – 7.28 (m, 2H), 2.65 – 2.53 (s, 3H). ¹H NMR (400 MHz, MeOD) δ = 9.05 – 9.04 (d, *J* = 1.4 Hz, 1H), 8.61 – 8.58 (d, *J* = 1.4 Hz, 1H), 7.96 – 7.92 (m, 2H), 7.18 – 7.11 (m, 2H), 2.94 – 2.30 (s, 3H). FTMS-ESI (+): *m/z*: calcd for [C₁₃H₁₁FN₃O]⁺: 244.0886 [M+H]⁺; found 244.0886 [C₁₃H₁₁FN₃O]⁺. FTMS-ESI (-): *m/z*: calcd for [C₁₃H₉FN₃O]⁻: 242.0730 [M+H]⁺; found 242.0765 [C₁₃H₉FN₃O]⁻.




Figure S1. ^1H NMR spectrum (400 MHz, Acetone) for 6-(4-fluorophenyl)-2-methylimidazo[1,2-*a*]pyrazin-3(7*H*)-one (**CLA-2**). δ = 9.31 – 9.30 (d, J = 1.3 Hz, 1H), 9.26 – 9.24 (d, J = 1.4 Hz, 1H), 8.24 – 8.19 (m, 2H), 7.33 – 7.28 (m, 2H), 2.65 – 2.53 (s, 3H).




Figure S2. ^1H NMR spectrum (400 MHz, MeOD) for 6-(4-fluorophenyl)-2-methylimidazo[1,2-*a*]pyrazin-3(7*H*)-one (**CLA-2**). δ = 9.05 – 9.04 (d, J = 1.4 Hz, 1H),

8.61 – 8.58 (d, $J = 1.4$ Hz, 1H), 7.96 – 7.92 (m, 2H), 7.18 – 7.11 (m, 2H), 2.94 – 2.30 (s, 3H).




Figure S3. FTMS-ESI (+) spectrum for 6-(4-fluorophenyl)-2-methylimidazo[1,2-*a*]pyrazin-3(7*H*)-one (**CLA-2**), m/z : calcd for $[C_{13}H_{11}FN_3O]^+$: 244.0886 $[M+H]^+$; found 244.0886 $[C_{13}H_{11}FN_3O]^+$.




Figure S4. FTMS-ESI (-) spectrum for 6-(4-fluorophenyl)-2-methylimidazo[1,2-*a*]pyrazin-3(7*H*)-one (**CLA-2**), m/z: calcd for $[\text{C}_{13}\text{H}_9\text{FN}_3\text{O}]^-$: 242.0730 $[\text{M}+\text{H}]^+$; found 242.0765 $[\text{C}_{13}\text{H}_9\text{FN}_3\text{O}]^-$.